AGM
VRDN icon

Alpine Global Management’s Viridian Therapeutics VRDN Stock Holding History

Alpine Global Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-13,794
Closed -$179K – 467
2024
Q2 		$179K Buy
+13,794
New +$191K 0.03% 320

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Alpine Global Management's VRDN Position: Q3 2024 in Review

Alpine Global Management sold out of Viridian Therapeutics (VRDN) in Q3 2024, closing a stake of 13,794 shares — an estimated $179K sold.

Alpine Global Management first reported a position in VRDN in Q2 2024 and held it in 1 quarter. The position peaked at $179K in Q2 2024. 165 funds tracked by Wall St. Rank hold VRDN as of Q3 2024.

  • Alpine Global Management reported no remaining Viridian Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Alpine Global Management sold 13,794 Viridian Therapeutics shares in Q3 2024, an estimated $179K.
  • Alpine Global Management first reported a position in Viridian Therapeutics in Q2 2024 and held it in 1 quarter.
  • Alpine Global Management's Viridian Therapeutics position peaked at $179K in Q2 2024.
  • 165 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2024.

Based on Alpine Global Management's 13F filing for Q3 2024, filed 14 Nov 2024.